GSK enters agreement to acquire 35Pharma Inc.

GSK has agreed to acquire 100% of privately held 35Pharma for $950 million in cash, gaining HS235 — an activin signalling inhibitor that completed Phase I healthy volunteer studies with imminent trials planned in PAH and PH‑HFpEF. HS235 is designed to reduce binding to BMP9/10 (potentially lowering bleeding risk) and may confer metabolic benefits, bolstering GSK’s RI&I pipeline; the global PH market is forecast to reach $18bn by 2032 with activin inhibitors expected to capture ~50%. Transaction is subject to customary regulatory clearances (Hart‑Scott‑Rodino, Canada Competition Act, Investment Canada Act) and represents a strategic, near‑term R&D/pipeline play rather than a large cash‑flow acquisition.

Analysis

Market structure: GSK (GSK) is the clear direct beneficiary — the $950m cash buy strengthens its RI&I pipeline and gives it early position in an activin-inhibitor class that Evaluate forecasts to be ~50% of a $18bn PH market by 2032 (~$9bn). Losers are small, pure‑play PH/activin biotechs (reduced M&A optionality and pricing leverage) and incumbent mono‑therapy vendors who face an expanded addressable population if bleeding risk is materially reduced. Cross-asset: expect modest positive equity re‑rating for GSK, negligible credit impact on GSK bonds, and a small uptick in implied vol for PH/biotech small caps around trial milestones.

Risk assessment: tail risks include late‑stage safety signals (bleeding, off‑target BMP9/10 effects) or regulatory setbacks that would wipe out acquisition premium; antitrust/Investment Canada clearances are low probability hurdles but could delay closing by 30–90 days. Immediate (days): HSR/Competition Act filings and share price drift; short (1–6 months): trial starts and early biomarker readouts; long (12–36+ months): Phase II/III efficacy/safety and payer HTA decisions. Hidden dependency: commercial value hinges on use with anticoagulants and payers accepting metabolic co‑benefits as added value.

Trade implications: establish a modest 2–3% long GSK equity position over the next 1–3 months to capture rerating on integration and trial starts; size add of 1–2% conditional on positive early PAH biomarker signals within 6–12 months. Use a 6–9 month call spread (buy 10–15% OTM, sell 20–30% OTM) equal to 1% notional to leverage upside while capping premium. Reduce small‑cap PH/activin biotech exposure by 2–4% and rotate into large diversified pharma to lower binary risk.

Contrarian angles: consensus likely underweights HS235’s metabolic benefits which can expand prescribing beyond traditional PH centers into cardiometabolic clinics — if confirmed, peak sales could exceed simple PH share assumptions. Conversely, the market may be underpricing clinical safety tail risk; if bleeding signals emerge, GSK downside could be 10–20% on re‑rating and write‑downs. Historical precedent: big‑pharma buys of single‑asset biotechs produced 5–25% acquirer re‑ratings on perceived strategic fit; watch for early data within 12 months as the decisive value inflection.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (GSK) over the next 1–3 months to capture rerating from the HS235 acquisition and imminent trial starts; plan to add an incremental 1–2% if early PAH biomarker signals are positive within 6–12 months.
• Buy a 6–9 month GSK call spread equal to ~1% notional: purchase calls ~10–15% OTM and sell calls ~20–30% OTM to gain asymmetric upside to a positive trial/clearance narrative while limiting premium outlay.
• Reduce aggregate exposure to small‑cap PH/activin pure plays by 2–4% of portfolio and rotate into large-cap diversified pharma (e.g., GSK) to lower binary clinical risk and capture consolidation-driven spread compression.
• Set event triggers to act: (a) add 2% to GSK on confirmation of trial initiation or positive safety biomarker within 90 days; (b) cut GSK exposure to breakeven or hedge with 3‑month puts if regulatory/competition filings extend beyond 90 days or if GSK issues >$1bn new debt/equity to fund acquisitions.